Sorafenib Tablet, Film Coated
Product Images NDC 13668-682

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sorafenib (NDC 13668-682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Bottle Label 1)

Label for Sorafenib Tablets, USP 200 mg film-coated tablets in a 30-tablet package. The label shows the active amount per tablet and storage instructions. Manufactured by Torrent Pharmaceuticals Limited, India, and marketed by Torrent Pharma Inc. The label includes the NDC 13668-682-30, prescription-only indication, and a barcode.*

FDA Label Image

Figure 01 (Figure 01)

A Kaplan-Meier survival curve chart comparing the survival probability (%) over months from randomization between sorafenib tablets and placebo. The chart shows survival probabilities on the vertical axis and months on the horizontal axis, with data for both sorafenib tablets (N=299) and placebo (N=303), including median survival times and numbers of patients at risk over time.*

FDA Label Image

Figure 02 (Figure 02)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over days from randomization between Sorafenib tablets (200 mg) and placebo groups. The chart shows higher progression-free survival for Sorafenib with median 167 days versus 84 days for placebo, including statistical data (HR 0.44, p < 0.000001).*

FDA Label Image

Figure 03 (Figure 03)

A Kaplan-Meier curve chart showing the proportion of progression-free survival over time in months for sorafenib tablets versus placebo. The chart compares survival rates of 207 patients taking sorafenib tablets and 210 patients on placebo, with the sorafenib group showing a higher proportion of progression-free survival over approximately 27 months. The number of patients at risk is indicated below the x-axis for both groups at multiple time points.*

FDA Label Image

Torrent Logo 1 (Logo 01)

FDA Label Image

Torrent Logo 2 (Logo 02)

FDA Label Image

Structure (Structure)

Chemical structure of sorafenib showing the arrangement of aromatic rings, trifluoromethyl, chloro, amide, and sulfonic acid functional groups in the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.